Highlights
- Potassium-competitive acid blockers (P-CABs), specifically vonoprazan, have revolutionized H. pylori eradication, with 10-14 day dual therapy showing non-inferiority to bismuth quadruple therapy and superior safety profiles.
- The global disease burden of H. pylori extends far beyond gastric cancer, with significant population attributable fractions for peptic ulcer disease (57%), MALT lymphoma (33%), and dyspepsia (7%).
- Emerging evidence links maternal H. pylori infection to increased risks of preeclampsia (RR 2.06), gestational diabetes, and fetal growth restriction, though routine screening during pregnancy remains exploratory.
- Tailored therapy based on genotypic resistance significantly improves eradication rates compared to empirical triple therapy, potentially shortening treatment duration to 7 days in susceptible cases.
Background
Helicobacter pylori (H. pylori) remains the most prevalent bacterial infection globally and is the primary driver of the gastric precancerous cascade. While historical treatment strategies relied heavily on proton pump inhibitor (PPI)-based triple therapy, the escalation of clarithromycin, metronidazole, and fluoroquinolone resistance has rendered these traditional regimens increasingly obsolete in many regions. The clinical focus has now shifted from mere eradication to a multifaceted approach that considers antimicrobial stewardship, the preservation of the gut microbiome, and the mitigation of systemic inflammatory consequences. Despite these advances, an “unfinished agenda” persists, characterized by global inequities in drug access, the need for precision-guided diagnostics, and the ongoing search for non-antibiotic alternatives.
Key Content
The P-CAB Revolution: Vonoprazan and Tegoprazan
One of the most significant shifts in H. pylori pharmacotherapy is the introduction of potassium-competitive acid blockers (P-CABs). Unlike traditional PPIs, P-CABs provide rapid, stable, and potent acid suppression that is independent of CYP2C19 polymorphisms. Recent clinical trials have focused on P-CAB-based high-dose dual therapy (HDDT), typically combining a P-CAB with amoxicillin.
In a multicenter randomized controlled trial (RCT) in China (PMID: 41781325), 10-day vonoprazan-amoxicillin dual therapy (V-DT) achieved eradication rates of 92.0% in intention-to-treat (ITT) analysis, which was non-inferior to both vonoprazan triple therapy (89.6%) and vonoprazan-bismuth quadruple therapy (88.8%). Notably, the incidence of adverse events was drastically lower in the V-DT group (6.4%) compared to quadruple therapy (49.6%). Similarly, another multicenter trial (PMID: 41330785) confirmed the efficacy and cost-effectiveness of V-DT using antibiotics from national centralized drug procurement, reducing costs by 44% without compromising outcomes.
The efficacy of different P-CABs, however, may not be uniform. A prospective multicenter study (PMID: 41923278) compared vonoprazan/amoxicillin (VA) against tegoprazan/amoxicillin (TA). The VA group demonstrated significantly higher eradication rates (89.3% vs. 76.1%, ITT), suggesting that vonoprazan may currently hold a pharmacokinetic advantage in dual therapy regimens, whereas tegoprazan may require dosing optimization to achieve comparable results.
Diagnostic Innovations and Tailored Therapy
Advancements in diagnostic technology are essential for precision-guided therapy. A prospective single-blind study (PMID: 41757610) evaluated a new miniaturized, column-free portable gas-mass spectrometry (GMS) test for the urea breath test (UBT), finding accuracy comparable to standard GMS while offering a more compact and cost-effective solution for clinical practice.
The K-CREATE Phase II study in Korea (PMID: 41734982) addressed the debate between tailored and empirical therapy. Patients receiving 7-day tailored therapy based on genotypic resistance (clarithromycin-based triple therapy for susceptible strains; bismuth quadruple therapy for resistant strains) achieved an 82.9% eradication rate, compared to 65.5% in the 14-day empirical triple therapy group. This indicates that molecular resistance testing can successfully reduce treatment duration while improving efficacy.
The Microbiome and Adjuvant Interventions
The ecological impact of H. pylori eradication is a growing concern. Bismuth quadruple therapy (BQT) is known to induce temporary gut dysbiosis. A randomized trial (PMID: 41520709) compared triple therapy plus probiotics (TTP) with BQT. While BQT remained superior in overall eradication (86.6% vs. 76.4%), TTP demonstrated better tolerability (17.8% vs. 28.7% adverse events) and, crucially, preserved gut microbiota stability. This suggests that in specific populations, such as those over 40 years where TTP showed non-inferiority, probiotic-augmented regimens may be preferable for minimizing microbiome disruption.
A meta-analysis of 28 RCTs (PMID: 41581709) evaluated probiotic monotherapy. While it significantly reduced bacterial load (indicated by UBT values) and improved gastrointestinal symptoms (SMD = -0.253), the standalone eradication rate was only 16.8%. These findings reinforce the role of probiotics as an adjunctive rather than a primary therapy.
Extragastric Manifestations and Systemic Impact
Recent literature has significantly expanded our understanding of H. pylori as a systemic pathogen. A comprehensive meta-analysis (PMID: 41236450) quantified the global burden beyond gastric cancer, estimating that H. pylori is responsible for 3.5 million preventable cases of peptic ulcer disease and 30 million cases of dyspepsia annually.
- Pregnancy Complications: Multiple meta-analyses (PMID: 41748262, 41619231) have identified H. pylori as a high-risk factor for preeclampsia (OR 2.91), gestational diabetes mellitus (RR 1.42), and hyperemesis gravidarum (RR 5.57). The association is particularly strong with CagA-positive strains. However, current evidence does not yet support routine screening or eradication during pregnancy.
- Cardiovascular Disease (CVD): Successful eradication was associated with significant reductions in total cholesterol, LDL, and trimethylamine N-oxide (TMAO) levels at one year post-treatment (PMID: 41894705), suggesting a potential role in reducing long-term CVD risk through modulation of lipid metabolism and systemic inflammation.
- Inflammatory Bowel Disease (IBD): In a striking contrast, a meta-analysis of 44 studies (PMID: 41709893) found a significantly lower prevalence of H. pylori in IBD patients (OR 0.43). This negative association suggests H. pylori may exert an immunomodulatory effect that protects against the development of Crohn’s disease and ulcerative colitis, particularly in Eastern populations.
- COPD: While H. pylori prevalence is higher in patients with severe COPD (PMID: 41868723), Mendelian randomization analysis failed to find a bidirectional causal relationship, suggesting the association may be driven by shared risk factors rather than direct causality.
Expert Commentary
The current state of H. pylori management reflects a transition toward “precision eradication.” The success of P-CAB-based dual therapy, particularly with vonoprazan, offers a simplified, safer, and highly effective alternative to complex quadruple regimens. However, experts caution that the “one-size-fits-all” approach is no longer tenable in the face of varying regional resistance patterns. For instance, the K-CREATE study underscores the power of tailored therapy, yet the infrastructure for genotypic testing is not universally available, especially in low-income regions like Tanzania where H. pylori prevalence remains high (54.3%, PMID: 41691179).
The debate surrounding H. pylori’s potential protective role in IBD and other autoimmune conditions remains a significant clinical dilemma. Clinicians must weigh the necessity of preventing gastric cancer against the theoretical risk of altering systemic immune homeostasis. Furthermore, while acupuncture and traditional Chinese medicine (PMID: 41824820) show promise as complementary therapies for gastric ulcers, higher-quality large-scale trials are needed before these can be formally integrated into international guidelines.
Conclusion
Optimizing H. pylori treatment requires a shift from empirical to evidence-based, precision-guided strategies. The adoption of 10-14 day P-CAB dual therapy as a first-line option is supported by high-quality RCTs showing excellent efficacy and safety. Advances in molecular diagnostics and miniaturized gas-mass spectrometry will be critical for implementing these strategies globally. Future research should prioritize closing the implementation gap in high-burden regions, refining the role of probiotics in microbiome protection, and investigating the systemic benefits of eradication on cardiovascular and metabolic health. As we address the “unfinished agenda,” antimicrobial stewardship remains the cornerstone of reducing the global burden of H. pylori-associated diseases.
References
- Rokkas T, Graham DY. The Unfinished Agenda in Helicobacter pylori Treatment: Resistance, Microbiome Effects, and Future Directions. Gastroenterology. 2026. PMID: 41905430.
- Chen X, et al. Efficacy and Safety of Vonoprazan-Based Dual, Triple, and Quadruple Therapies for Helicobacter pylori Eradication. Helicobacter. 2026. PMID: 41781325.
- Li Y, et al. The effect of Helicobacter pylori infection on pregnancy and fetal complications: a systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2026. PMID: 41748262.
- Park JY, et al. 14-day Empirical Therapy Compared with 7-day Tailored Therapy for Eradication in Korea: Results of the K-CREATE Phase II Study. Yonsei Med J. 2026. PMID: 41734982.
- Huang W, et al. Beneficial effects of a compound probiotic in Helicobacter pylori-infected patients aged over 40 years: An open-label randomised clinical trial. Int J Antimicrob Agents. 2026. PMID: 41520709.
- Zheng J, et al. To eradicate or not? In patients with inflammatory bowel disease: an updated systematic review and meta-analysis. Front Med (Lausanne). 2026. PMID: 41709893.
- Hajishafiha M, et al. Helicobacter pylori Infection as a High-Risk Factor for Preeclampsia: A Systematic Review and Meta-Analysis. Dig Dis. 2026. PMID: 41619231.
- Sun L, et al. Randomized Comparison of Vonoprazan-Amoxicillin Dual Therapy Versus Bismuth Quadruple Therapies: Evaluating National Centralized Drug Procurement Antibiotics. J Gastroenterol Hepatol. 2026. PMID: 41330785.